WO1989001940A1
(en)
*
|
1987-09-04 |
1989-03-09 |
Biogen, Inc. |
Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
|
IL87902A0
(en)
*
|
1987-10-08 |
1989-03-31 |
Dana Farber Cancer Inst Inc |
Soluble human cd4 fragments and applications thereof
|
US6004781A
(en)
*
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
ZA89430B
(en)
*
|
1988-01-22 |
1989-10-25 |
Gen Hospital Corp |
Cloned genes encoding ig-cd4 fusion proteins and the use thereof
|
US5681566A
(en)
*
|
1988-10-24 |
1997-10-28 |
3I Research Exploitation Limited |
Antibody conjugates with two or more covalently linked FC regions
|
GB8824869D0
(en)
*
|
1988-10-24 |
1988-11-30 |
Stevenson G T |
Synthetic antibody
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
EP0460021A4
(en)
*
|
1989-02-23 |
1992-08-26 |
Seragen, Inc. |
Chimeric toxin
|
US6267964B1
(en)
|
1989-08-01 |
2001-07-31 |
Affibody Technology Sweden Ab |
Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
|
FR2650598B1
(fr)
*
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
CA2065010A1
(en)
*
|
1989-08-23 |
1991-02-24 |
Brian Seed |
Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
EP0417563B1
(de)
*
|
1989-09-12 |
2000-07-05 |
F. Hoffmann-La Roche Ag |
TNF-bindende Proteine
|
US5767072A
(en)
*
|
1989-09-14 |
1998-06-16 |
Board Of Regents, The University Of Texas System |
Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
|
CA2065029A1
(en)
*
|
1989-09-14 |
1991-03-15 |
Ellen S. Vitetta |
Therapeutic compositions; methods for treatment of hiv infections
|
US5116944A
(en)
*
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
AU7217891A
(en)
*
|
1990-02-13 |
1991-09-03 |
Oxford Virology Plc |
Therapeutic agents, and intermediates for the synthesis thereof
|
US5498538A
(en)
*
|
1990-02-15 |
1996-03-12 |
The University Of North Carolina At Chapel Hill |
Totally synthetic affinity reagents
|
US5614612A
(en)
*
|
1990-03-09 |
1997-03-25 |
Haigwood; Nancy L. |
Purified gp120 compositions retaining natural conformation
|
US5521288A
(en)
*
|
1990-03-26 |
1996-05-28 |
Bristol-Myers Squibb Company |
CD28IG fusion protein
|
US5750371A
(en)
*
|
1990-04-27 |
1998-05-12 |
Takeda Chemical Industries Ltd |
Water-soluble mutein of FGF receptor, DNA and production thereof
|
AT396939B
(de)
*
|
1990-05-29 |
1993-12-27 |
Alois Dipl Ing Dr Jungbauer |
Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
|
US5349053A
(en)
*
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
CA2090105A1
(en)
*
|
1990-08-29 |
1992-03-01 |
Jean-Paul Soulillou |
Protein polyligands joined to a stable protein core
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
DE4037837A1
(de)
*
|
1990-11-28 |
1992-06-04 |
Behringwerke Ag |
Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
|
JP3242916B2
(ja)
*
|
1990-12-14 |
2001-12-25 |
セル ジェネシス,インコーポレイティド |
レセプター関連シグナル変換系のためのキメラ鎖
|
US7070991B2
(en)
|
1991-02-08 |
2006-07-04 |
Progenics Pharmaceuticals, Inc. |
Cells expressing a CD4-IgG2 chimeric heterotetramer
|
WO1992013559A1
(en)
*
|
1991-02-08 |
1992-08-20 |
Progenics Pharmaceuticals, Inc. |
CD4-GAMMA1 AND CD4-IgG1 CHIMERAS
|
AU660662B2
(en)
|
1991-02-08 |
1995-07-06 |
Progenics Pharmaceuticals, Inc. |
CD4-gamma2 and CD4-IgG2 chimeras
|
US5234905A
(en)
*
|
1991-02-22 |
1993-08-10 |
University Of Colorado Foundation, Inc. |
Soluble CD4 molecules modified to prolong circulating half-life
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
US5547853A
(en)
*
|
1991-03-12 |
1996-08-20 |
Biogen, Inc. |
CD2-binding domain of lymphocyte function associated antigen 3
|
US5212075A
(en)
*
|
1991-04-15 |
1993-05-18 |
The Regents Of The University Of California |
Compositions and methods for introducing effectors to pathogens and cells
|
ATE170559T1
(de)
*
|
1991-05-31 |
1998-09-15 |
Genentech Inc |
Behandlung der hiv-assoziierten immun- thrombopenie purpura
|
US5891841A
(en)
*
|
1991-06-11 |
1999-04-06 |
The Center For Blood Research, Inc. |
Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5623053A
(en)
*
|
1992-01-10 |
1997-04-22 |
California Institute Of Technology |
Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
|
US5525487A
(en)
*
|
1992-01-27 |
1996-06-11 |
Icos Corporation |
DNA encoding I-CAM related protein
|
US6818743B1
(en)
|
1992-01-27 |
2004-11-16 |
Icos Corporation |
I-CAM related protein
|
US5989843A
(en)
*
|
1992-01-27 |
1999-11-23 |
Icos Corporation |
Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
|
US5532127A
(en)
*
|
1992-01-27 |
1996-07-02 |
Icos Corporation |
Assay for 1-CAM related protein expression
|
US5837822A
(en)
*
|
1992-01-27 |
1998-11-17 |
Icos Corporation |
Humanized antibodies specific for ICAM related protein
|
US5700658A
(en)
*
|
1992-01-27 |
1997-12-23 |
Icos Corporation |
ICAM-4 materials and methods
|
US5702917A
(en)
*
|
1992-01-27 |
1997-12-30 |
Icos Corporation |
Polynucleotides encoding human ICAM-4
|
US5753502A
(en)
*
|
1993-08-05 |
1998-05-19 |
Icos Corporation |
Neuron-specific ICAM-4 promoter
|
WO1993014776A1
(en)
*
|
1992-01-27 |
1993-08-05 |
Icos Corporation |
Icam-related protein
|
US5773293A
(en)
*
|
1992-01-27 |
1998-06-30 |
Icos Corporation |
Anti-ICAM-4 antibodies and hybridomas
|
US5880268A
(en)
*
|
1992-01-27 |
1999-03-09 |
Icos Corporation |
Modulators of the interaction between ICAM-R and αd /CD18
|
US6100383A
(en)
*
|
1992-01-27 |
2000-08-08 |
Icos Corporation |
Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
|
US6153395A
(en)
*
|
1992-01-27 |
2000-11-28 |
Icos Corporation |
ICAM-related protein
|
US5852170A
(en)
*
|
1992-01-27 |
1998-12-22 |
Icos Corporation |
ICAM-4 materials and methods
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
GB9219562D0
(en)
|
1992-03-11 |
1992-10-28 |
Prendergast Kennet F |
Anti-viral peptides
|
WO1993018160A1
(en)
*
|
1992-03-11 |
1993-09-16 |
Kenneth Francis Prendergast |
Anti-viral fusion peptides
|
JPH0640945A
(ja)
*
|
1992-07-23 |
1994-02-15 |
Kureha Chem Ind Co Ltd |
Fcフラグメント結合抗腫瘍剤
|
EP0664710A4
(en)
*
|
1992-08-07 |
1998-09-30 |
Progenics Pharm Inc |
CD4-GAMMA2 AND CD4-IgG2 NON-PEPTIDYL CONJUGATE IMMUNOCONJUGATES AND USES THEREOF.
|
WO1994004689A1
(en)
*
|
1992-08-14 |
1994-03-03 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant toxin with increased half-life
|
DE4228839A1
(de)
|
1992-08-29 |
1994-03-03 |
Behringwerke Ag |
Verfahren zum Nachweis und zur Bestimmung von Mediatoren
|
WO1994006469A1
(en)
*
|
1992-09-18 |
1994-03-31 |
La Jolla Institute For Allergy And Immunology |
Hiv fusion polypeptide
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
ZA955642B
(en)
*
|
1994-07-07 |
1997-05-06 |
Ortho Pharma Corp |
Lyophilized imaging agent formulation
|
US5910481A
(en)
*
|
1995-11-13 |
1999-06-08 |
Immuno Ag |
Hybrid proteins with modified activity
|
US5723125A
(en)
*
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
AU730816B2
(en)
*
|
1996-02-12 |
2001-03-15 |
Cedars-Sinai Medical Center |
Vitamin D response element binding protein
|
US6469144B1
(en)
|
1996-04-01 |
2002-10-22 |
Genentech, Inc. |
Apo-2LI and Apo-3 polypeptides
|
US6342586B1
(en)
|
1996-06-10 |
2002-01-29 |
Progenics Pharmaceuticals, Inc. |
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
|
AU727606B2
(en)
|
1996-07-12 |
2000-12-14 |
Genentech Inc. |
Gamma-heregulin
|
WO1998002540A1
(en)
|
1996-07-12 |
1998-01-22 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
ES2246069T3
(es)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
CA2287911C
(en)
|
1997-05-15 |
2014-05-06 |
Genentech, Inc. |
Apo-2 receptor
|
US6291643B1
(en)
|
1997-06-05 |
2001-09-18 |
Board Of Reports, The University Of Texas System |
Apaf-1 an activator of caspase-3
|
AU740227B2
(en)
|
1997-06-18 |
2001-11-01 |
Genentech Inc. |
Apo-2DcR
|
EP0893507A1
(en)
|
1997-07-25 |
1999-01-27 |
Institut Gustave Roussy |
Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
|
EP1037927B1
(en)
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
EP1088084B1
(en)
|
1998-06-15 |
2006-09-13 |
GTC Biotherapeutics, Inc. |
Erythropoietin analog-human serum albumin fusion protein
|
WO2000004148A1
(en)
|
1998-07-15 |
2000-01-27 |
Genentech, Inc. |
Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
EP1141314A2
(en)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
ATE384795T1
(de)
|
1998-12-31 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Modifizierte hiv env polypeptide
|
US6656728B1
(en)
|
1999-02-08 |
2003-12-02 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
DK1200479T3
(da)
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
CA2399832C
(en)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2267026A1
(en)
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2002026781A2
(en)
|
2000-09-26 |
2002-04-04 |
Genentech, Inc. |
Ige receptor antagonists
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AU2002248571B2
(en)
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
CA2454618C
(en)
|
2001-07-24 |
2012-04-03 |
Biogen Idec Ma, Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
IL160289A0
(en)
|
2001-08-30 |
2004-07-25 |
Biorexis Pharmaceutical Corp |
Modified transferrin fusion proteins
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
AU2002316578A1
(en)
|
2001-08-31 |
2003-03-18 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
EP2354791A1
(en)
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
PT1463751E
(pt)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Proteínas de fusão de albumina
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
EP1369128A1
(en)
|
2002-06-07 |
2003-12-10 |
Procorde GmbH |
Inhibitors of glycoprotein VI and their therapeutic use
|
US20070071744A1
(en)
|
2002-06-07 |
2007-03-29 |
Gotz Munch |
Agents which bind to epitopes of glycoprotein VI
|
US7531178B2
(en)
|
2002-06-07 |
2009-05-12 |
Trigen Gmbh |
Immunoadhesin comprising a glycoprotein VI domain
|
BRPI0317376B8
(pt)
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
RU2369616C2
(ru)
|
2003-12-30 |
2009-10-10 |
Мерк Патент Гмбх |
Слитые белки il-7
|
WO2005066348A2
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
WO2005070967A2
(en)
|
2004-01-22 |
2005-08-04 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
PL1729795T3
(pl)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
WO2005115436A1
(en)
|
2004-05-07 |
2005-12-08 |
Astellas Us Llc |
Soluble lfa-3 polypeptide for treating viral disorders
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
JP4833991B2
(ja)
|
2004-11-02 |
2011-12-07 |
アレス トレーディング ソシエテ アノニム |
哺乳動物細胞のための無血清細胞培養培地
|
US8273553B2
(en)
|
2004-11-02 |
2012-09-25 |
Ares Trading S.A. |
Production of growth hormone in serum-free cell culture medium for mammalian cells
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
PL1966238T3
(pl)
|
2005-12-30 |
2012-09-28 |
Merck Patent Gmbh |
Warianty interleukiny-12p40 o polepszonej stabilności
|
CN101351477B
(zh)
|
2005-12-30 |
2011-11-16 |
默克专利有限公司 |
具有降低的免疫原性的抗cd19抗体
|
ATE524493T1
(de)
|
2006-07-24 |
2011-09-15 |
Biorexis Pharmaceutical Corp |
Exendin-fusionsproteine
|
PT2059536E
(pt)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Anticorpos otimizados que visam cd19
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US20120282245A1
(en)
|
2006-10-03 |
2012-11-08 |
Biogen Idec Ma Inc. |
Biomarkers and assays for the treatment of cancer
|
EP2612868B1
(en)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
CA2960659C
(en)
|
2007-11-09 |
2021-07-13 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
MX2011011044A
(es)
|
2009-04-22 |
2011-11-04 |
Merck Patent Gmbh |
Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
JP6849590B2
(ja)
*
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
WO2017055522A1
(en)
|
2015-09-29 |
2017-04-06 |
Academisch Medisch Centrum |
Stabilized env proteins of hiv
|
CN108712911A
(zh)
|
2015-12-30 |
2018-10-26 |
科达制药股份有限公司 |
抗体及其缀合物
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|